Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure

Table 2 Comparison of patients with or without cardiac event

	Event (-) (n=77)	Event (+) (n=59)	P value
Age, years	71 ± 10	72 ± 14	0.687
Male, n (%)	40 (52)	36 (61)	0.480
NYHA functional class, II/III/IV	49/21/6	22/25/13	0.005
Etiology, n (%)			0.348
Dilated cardiomyopathy	12 (16)	17 (29)	-
Valvular heart disease	24 (31)	14 (24)	-
Ischemic heart disease	17 (22)	13 (22)	-
Hypertensive heart disease	8 (10)	6 (10)	-
Hypertrophic cardiomyopathy	6 (8)	3 (5)	-
Others	10 (13)	6 (10)	-
Presentation profile
Systolic pressure, mmHg	116 ± 18	118 ± 19	0.598
Diastolic pressure, mmHg	73 ± 9	74 ± 11	0.780
Body mass index, kg/m²	22.0 ± 4.4	21.4 ± 3.3	0.413
eGFR, ml/min/1.73m²	66 ± 27	57 ± 24	0.046
Blood biomarkers
Albumin, g/dl	3.5 ± 0.6	3.5 ± 0.6	0.539
Total cholesterol, mg/dl	169 ± 37	163 ± 42	0.398
Triglyceride, mg/dl	97 ± 48	84 ± 45	0.132
LDLc, mg/dl	101 ± 37	99 ± 37	0.731
HDLc, mg/dl	55 ± 29	52 ± 12	0.437
hsCRP, mg/dl (IQR)	0.174 (0.058-0.330)	0.267 (0.073-0.722)	0.308
BNP, pg/ml (IQR)	453 (248–1249)	512 (169–1255)	0.049
Omentin-1, ng/ml (IQR)	479 (323–661)	139 (57–402)	<0.001
Echocardiographic data
LV end-diastolic diameter, mm	53 ± 10	57 ± 10	0.011
LV ejection fraction, %	56 ± 17	45 ± 16	<0.001
Medications, n (%)
ACE inhibitors and/or ARBs	54 (70)	48 (81)	0.134
β blockers	52 (68)	51 (86)	0.029
Statins	23 (30)	28 (47)	0.460
Ca channel blockers	29 (3)	8 (14)	0.964

Data are presented as mean±SD or % unless otherwise indicated; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein cholesterol; LV, left ventricular; NYHA, New York Heart Association.

ISSN: 1475-2840